Many studies evaluated the efficacy of various combinations of PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) and ICI agents [anti-PD-1 antibodies (pembrolizumab and nivolumab), anti-PD-1 antibodies (avelumab, atezolizumab, and durvalumab(and anti-CTLA-4 antibodies (tremelimumab)] in the treatment of patients with ovarian cancer (Table 1). The gene discussed is PARP1; the disease is ovarian cancer.